Relmada Therapeutics (RLMD) EBT (2012 - 2026)
Relmada Therapeutics' (RLMD) quarterly EBT came in at -$56.4 million in Q1 2026, down 216.54% year-on-year from $48.4 million in Q1 2025, and down 182.54% on a QoQ basis from -$20.0 million in Q4 2025.
Relmada Therapeutics (RLMD) EBT (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of EBT data on file, last reported at -$56.4 million in Q1 2026.
- On a quarterly basis, EBT fell 216.54% year-over-year to -$56.4 million in Q1 2026; TTM through Mar 2026 was -$96.4 million, a 24.78% decrease from a year earlier, with the FY2025 full-year figure at -$64.6 million, up 19.72% from the prior year.
- EBT for Q1 2026 stood at -$56.4 million, down from -$20.0 million in the prior quarter.
- Over the last five years, EBT for RLMD reached as high as -$9.9 million in Q2 2025 and fell as low as -$56.4 million in Q1 2026.
- Historically, EBT has averaged -$27.7 million across 5 years, with a median of -$24.7 million in 2023.
- Across the five-year window, EBT surged 69.99% in 2022 and sank 216.54% in 2026, its largest moves.
- Year by year, EBT stood at -$39.1 million in 2022, then jumped by 34.58% to -$25.6 million in 2023, then increased by 27.91% to -$18.4 million in 2024, then slipped by 8.25% to -$20.0 million in 2025, then slumped by 182.54% to -$56.4 million in 2026.
- Per Business Quant data, the three most recent EBT figures were -$56.4 million in Q1 2026, -$20.0 million in Q4 2025, and -$10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | -56.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.43 Mn |
| Dec 31, 2025 | -19.97 Mn |
| Sep 30, 2025 | -10.08 Mn |
| Jun 30, 2025 | -9.90 Mn |
| Mar 31, 2025 | -17.83 Mn |
| Dec 31, 2024 | -18.45 Mn |
| Sep 30, 2024 | -22.75 Mn |
| Jun 30, 2024 | -18.21 Mn |
| Mar 31, 2024 | -37.08 Mn |
| Dec 31, 2023 | -25.59 Mn |
| Sep 30, 2023 | -21.41 Mn |
| Jun 30, 2023 | -24.70 Mn |
| Mar 31, 2023 | -26.99 Mn |
| Dec 31, 2022 | -39.12 Mn |
| Sep 30, 2022 | -38.74 Mn |
| Jun 30, 2022 | -45.51 Mn |
| Mar 31, 2022 | -38.30 Mn |
| Dec 31, 2021 | -130.38 Mn |
| Sep 30, 2021 | -42.65 Mn |
| Jun 30, 2021 | -26.46 Mn |